Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity-Reference-Cited by-同舟云学术

Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity

Published:2004-10-25 Issue:1 Volume:35 Page:17-23
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Zwaveling J,Bredius R G M,Cremers S C L M,Ball L M,Lankester A C,Teepe-Twiss I M,Egeler R M,den Hartigh J,Vossen J M

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1704707.pdf

Reference26 articles.

1. Copelan EA, Bechtel TP, Avalos BR et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121–1124.

2. Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998; 20: 543–549.

3. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055–3060.

4. Kashyap A, Wingard J, Cagnoni P et al. Intravenous vs oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2000; 8: 493–500.

5. Hassan Z, Ljungman P, Ringdén O et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant 2001; 27: 479–485.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of prophylactic echinocandin on the development of neurological complications in patients receiving busulfan‐containing conditioning regimens for stem cell transplantation: A single‐center retrospective study;Pediatric Transplantation;2024-04-10

2. Population Pharmacokinetic Modeling for Twice-Daily Intravenous Busulfan in a Large Cohort of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation—A 10-Year Single-Center Experience;Pharmaceutics;2023-12-20

3. Role of therapeutic drug monitoring of intravenous Busulfan for prevention of sinusoidal obstructive syndrome in children;Pediatric Transplantation;2022-03-28

4. Characterization of drug–drug interactions on the pharmacokinetic disposition of busulfan in paediatric patients during haematopoietic stem cell transplantation conditioning;British Journal of Clinical Pharmacology;2021-12-20

5. Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia;Frontiers in Pediatrics;2021-12-10